TFAP2C

Across TCGA pan-cancer cohorts, TFAP2C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TFAP2C data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TFAP2C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TFAP2C expression acts as an unfavorable survival marker.

BLCA, CESC, and PRAD are the cancer types where TFAP2C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.123	0.471	.003	10	view →
CESC	OS	Median	II,III,IV	0.524	0.829	.027	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	0.599	0.870	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TFAP2C–BLCA (DFS)

Open the BLCA breakdown →